Sustained Release Travoprost: Phase IIb started

Ocular Therapeutix began a double-blind, U.S. Phase IIb trial to compare a single dose of 0.36 mg Sustained Release Travoprost vs. twice-daily timolol eye drops in about 80 patients. ...